Hashimoto encephalopathy: literature review
B. Xu
Department of Internal Medicine, Drum Tower Hospital, Nanjing University Medical School, Nanjing, China
Search for more papers by this authorJ. Lopes
Department of Physician Assistant, Central Michigan University, Mount Pleasant, MI, USA
Search for more papers by this authorJ. Blamoun
Department of Physician Assistant, Central Michigan University, Mount Pleasant, MI, USA
Department of Critical Care, Michigan Health, Midland, MI, USA
Search for more papers by this authorCorresponding Author
L. Li
Department of Physician Assistant, Central Michigan University, Mount Pleasant, MI, USA
Correspondence
L. Li, Central Michigan University, Mount Pleasant, MI, USA.
Email: [email protected]
Search for more papers by this authorB. Xu
Department of Internal Medicine, Drum Tower Hospital, Nanjing University Medical School, Nanjing, China
Search for more papers by this authorJ. Lopes
Department of Physician Assistant, Central Michigan University, Mount Pleasant, MI, USA
Search for more papers by this authorJ. Blamoun
Department of Physician Assistant, Central Michigan University, Mount Pleasant, MI, USA
Department of Critical Care, Michigan Health, Midland, MI, USA
Search for more papers by this authorCorresponding Author
L. Li
Department of Physician Assistant, Central Michigan University, Mount Pleasant, MI, USA
Correspondence
L. Li, Central Michigan University, Mount Pleasant, MI, USA.
Email: [email protected]
Search for more papers by this authorAbstract
Hashimoto encephalopathy (HE) presents as an encephalopathy without central nervous system infection or tumor. HE is associated with autoimmune thyroiditis and is thus considered to be an autoimmune disorder. The prevalence of HE is low, but death and status epilepticus have been reported. HE manifests with a wide range of symptoms that include behavioral changes and confusion. Elevated thyroid antibodies are present in the majority of cases and are required for the diagnosis of HE. Normal brain MRI findings are found in the majority of patients diagnosed with HE. The most consistent CSF abnormality noted in HE patients is the presence of elevated protein. Most HE patients respond well to steroid therapy. Clinical improvements are also observed with IV immunoglobulin and plasmapheresis. In conclusion, it is now generally accepted that the diagnosis of HE must include encephalopathy characterized by cognitive impairment associated with psychiatric features, such as hallucinations, delusions, and paranoia. Autoimmune encephalitis and prion disease should be considered in the differential diagnosis due to the similarity of the clinical features of these conditions to those of HE.
References
- 1Olmez I, Moses H, Sriram S, Kirshner H, Lagrange AH, Pawate S. Diagnostic and therapeutic aspects of Hashimoto's encephalopathy. J Neurol Sci. 2013; 331: 67–71.
- 2Brain L, Jellinek EH, Ball K. Hashimoto's disease and encephalopathy. Lancet. 1966; 2: 512–514.
- 3Chong JY, Rowland LP, Utiger RD. Hashimoto encephalopathy: syndrome or myth? Arch Neurol. 2003; 60: 164–171.
- 4Chaigne B, Mercier E, Garot D, Legras A, Dequin PF, Perrotin D. Hashimoto's encephalopathy in the intensive care unit. Neurocrit Care. 2013; 18: 386–390.
- 5Chaigne B, Beaufils E, Jouan Y, et al. [Hashimoto's encephalopathy]. Rev Med Interne. 2012; 33: 390–395.
- 6Sadan O, Seyman E, Ash EL, Kipervasser S, Neufeld MY. Adult-onset temporal lobe epilepsy, cognitive decline, multi-antiepileptic drug hypersensitivity, and Hashimoto's encephalopathy: two case studies. Epilepsy Behav Case Rep. 2013; 1: 132–135.
- 7Mahmud FH, Lteif AN, Renaud DL, Reed AM, Brands CK. Steroid-responsive encephalopathy associated with Hashimoto's thyroiditis in an adolescent with chronic hallucinations and depression: case report and review. Pediatrics. 2003; 112: 686–690.
- 8Kothbauer-Margreiter I, Sturzenegger M, Komor J, Baumgartner R, Hess CW. Encephalopathy associated with Hashimoto thyroiditis: diagnosis and treatment. J Neurol. 1996; 243: 585–593.
- 9Blanchin S, Coffin C, Viader F, et al. Anti-thyroperoxidase antibodies from patients with Hashimoto's encephalopathy bind to cerebellar astrocytes. J Neuroimmunol. 2007; 192: 13–20.
- 10Gini B, Lovato L, Laura L, et al. Novel autoantigens recognized by CSF IgG from Hashimoto's encephalitis revealed by a proteomic approach. J Neuroimmunol. 2008; 196: 153–158.
- 11Ferracci F, Moretto G, Candeago RM, et al. Antithyroid antibodies in the CSF: their role in the pathogenesis of Hashimoto's encephalopathy. Neurology. 2003; 60: 712–714.
- 12Lee SW, Donlon S, Caplan JP. Steroid responsive encephalopathy associated with autoimmune thyroiditis (SREAT) or Hashimoto's encephalopathy: a case and review. Psychosomatics. 2011; 52: 99–108.
- 13Chaudhuri A, Behan PO. The clinical spectrum, diagnosis, pathogenesis and treatment of Hashimoto's encephalopathy (recurrent acute disseminated encephalomyelitis). Curr Med Chem. 2003; 10: 1945–1953.
- 14Fujii A, Yoneda M, Ito T, et al. Autoantibodies against the amino terminal of alpha-enolase are a useful diagnostic marker of Hashimoto's encephalopathy. J Neuroimmunol. 2005; 162: 130–136.
- 15Yoneda M, Fujii A, Ito A, Yokoyama H, Nakagawa H, Kuriyama M. High prevalence of serum autoantibodies against the amino terminal of alpha-enolase in Hashimoto's encephalopathy. J Neuroimmunol. 2007; 185: 195–200.
- 16McCabe DJ, Burke T, Connolly S, Hutchinson M. Amnesic syndrome with bilateral mesial temporal lobe involvement in Hashimoto's encephalopathy. Neurology. 2000; 54: 737–739.
- 17Nakagawa H, Yoneda M, Fujii A, Kinomoto K, Kuriyama M. Hashimoto's encephalopathy presenting with progressive cerebellar ataxia. J Neurol Neurosurg Psychiatry. 2007; 78: 196–197.
- 18McGinley J, McCabe DJ, Fraser A, Casey E, Ryan T, Murphy R. Hashimoto's encephalopathy; an unusual cause of status epilepticus. Ir Med J. 2000; 93: 118.
- 19Arya R, Anand V, Chansoria M. Hashimoto encephalopathy presenting as progressive myoclonus epilepsy syndrome. Eur J Paediatr Neurol. 2013; 17: 102–104.
- 20Gücüyener K, Serdaroğlu A, Bideci A, Yazman Y, Soysal AS, Cinaz P. Tremor and myoclonus heralding Hashimoto's encephalopathy. J Pediatr Endocrinol Metab. 2000; 13: 1137–1141.
- 21Gómez-Bernal GJ, Reboreda A, Romero F, Bernal MM, Gómez F. A case of Hashimoto's encephalopathy manifesting as psychosis. Prim Care Companion J Clin Psychiatry. 2007; 9: 318–319.
- 22Wilcox RA, To T, Koukourou A, Frasca J. Hashimoto's encephalopathy masquerading as acute psychosis. J Clin Neurosci. 2008; 15: 1301–1304.
- 23Castillo P, Woodruff B, Caselli R, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol. 2006; 63: 197–202.
- 24Ferracci F, Carnevale A. The neurological disorder associated with thyroid autoimmunity. J Neurol. 2006; 253: 975–984.
- 25Vasconcellos E, Piña-Garza JE, Fakhoury T, Fenichel GM. Pediatric manifestations of Hashimoto's encephalopathy. Pediatr Neurol. 1999; 20: 394–398.
- 26Liu CY, Tseng MC, Lin PH. Encephalopathy associated with autoimmune thyroid disease (Hashimoto's thyroiditis) presenting as depression: a case report. Gen Hosp Psychiatry. 2011; 33: 641.e7-9.
- 27Lin ST, Chen CS, Yang P, Chen CC. Manic symptoms associated with Hashimoto's encephalopathy: response to corticosteroid treatment. J Neuropsychiatry Clin Neurosci. 2011; 23: E20–E21.
- 28Hilberath JM, Schmidt H, Wolf GK. Steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT): case report of reversible coma and status epilepticus in an adolescent patient and review of the literature. Eur J Pediatr. 2014; 173: 1263–1273.
- 29Visée H, Mabiglia C, Vanderaspoilden V, Gazagnes MD, Glibert G. Recurrent status epilepticus associated with Hashimoto's encephalopathy. Epilepsy Behav Case Rep. 2013; 1: 113–117.
- 30Jamrozik Z, Janik P, Kiljański J, Kwieciński H. [Hashimoto's encephalopathy. Case report and literature review]. Neurol Neurochir Pol. 2004; 38: 55–59.
- 31Prat S, Jouan Y, Magnant J, Graux J, El-Hage W. Hashimoto encephalopathy diagnosis after 40 years of a schizophrenia-like disorder. Schizophr Res. 2012; 139: 269–270.
- 32Sirois F. Steroid psychosis: a review. Gen Hosp Psychiatry. 2003; 25: 27–33.
- 33Hernández Echebarría LE, Saiz A, Graus F, et al. Detection of 14-3-3 protein in the CSF of a patient with Hashimoto's encephalopathy. Neurology. 2000; 54: 1539–1540.
- 34Salazar R, Mehta C, Zaher N, Miller D. Opsoclonus as a manifestation of Hashimoto's encephalopathy. J Clin Neurosci. 2012; 19: 1465–1466.
- 35Canelo-Aybar C, Loja-Oropeza D, Cuadra-Urteaga J, Romani-Romani F. Hashimoto's encephalopathy presenting with neurocognitive symptoms: a case report. J Med Case Rep. 2010; 4: 337.
- 36Mamoudjy N, Korff C, Maurey H, et al. Hashimoto's encephalopathy: identification and long-term outcome in children. Eur J Paediatr Neurol. 2013; 17: 280–287.
- 37Cook MK, Malkin M, Karafin MS. The use of plasma exchange in Hashimoto's encephalopathy: a case report and review of the literature. J Clin Apher. 2015; 30: 188–192.
- 38de Holanda NC, de Lima DD, Cavalcanti TB, Lucena CS, Bandeira F. Hashimoto's encephalopathy: systematic review of the literature and an additional case. J Neuropsychiatry Clin Neurosci. 2011; 23: 384–390.
- 39Mirabelli-Badenier M, Biancheri R, Morana G, et al. Anti-NMDAR encephalitis misdiagnosed as Hashimoto's encephalopathy. Eur J Paediatr Neurol. 2014; 18: 72–74.
- 40Leypoldt F, Armangue T, Dalmau J. Autoimmune encephalopathies. Ann N Y Acad Sci. 2015; 1338: 94–114.
- 41Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016; 15: 391–404.
- 42Onesti E, Koudriavtseva T, Galiè E, Anelli V, Jandolo B. A possible case of Hashimoto's encephalopathy after surgery and radiometabolic therapy for thyroid carcinoma. Neurol Sci. 2013; 34: 1489–1491.
- 43Schiess N, Pardo CA. Hashimoto's encephalopathy. Ann N Y Acad Sci. 2008; 1142: 254–265.
- 44Alink J, De Vries TW. Unexplained seizures, confusion or hallucinations: think Hashimoto encephalopathy. Acta Paediatr. 2008; 97: 451–453.
- 45Tamagno G, Celik Y, Simó R, et al. Encephalopathy associated with autoimmune thyroid disease in patients with Graves’ disease: clinical manifestations, follow-up, and outcomes. BMC Neurol. 2010; 10: 27.
- 46Chen N, Qin W, Wei C, Wang X, Li K. Time course of Hashimoto's encephalopathy revealed by MRI: report of two cases. J Neurol Sci. 2011; 300: 169–172.
- 47Tang Y, Xing Y, Lin MT, Zhang J, Jia J. Hashimoto's encephalopathy cases: Chinese experience. BMC Neurol. 2012; 12: 60.
- 48Payer J, Petrovic T, Lisy L, Langer P. Hashimoto encephalopathy: a rare intricate syndrome. Int J Endocrinol Metab. 2012; 10: 506–514.
- 49Schäuble B, Castillo PR, Boeve BF, Westmoreland BF. EEG findings in steroid-responsive encephalopathy associated with autoimmune thyroiditis. Clin Neurophysiol. 2003; 114: 32–37.
- 50Fatourechi V. Hashimoto's encephalopathy: myth or reality? An endocrinologist's perspective. Best Pract Res Clin Endocrinol Metab. 2005; 19: 53–66.
- 51Ochi H, Horiuchi I, Araki N, et al. Proteomic analysis of human brain identifies alpha-enolase as a novel autoantigen in Hashimoto's encephalopathy. FEBS Lett. 2002; 528: 197–202.
- 52Mocellin R, Walterfang M, Velakoulis D. Hashimoto's encephalopathy: epidemiology, pathogenesis and management. CNS Drugs. 2007; 21: 799–811.
- 53Mahad DJ, Staugaitis S, Ruggieri P, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis and primary CNS demyelination. J Neurol Sci. 2005; 228: 3–5.
- 54Berger I, Castiel Y, Dor T. Paediatric Hashimoto encephalopathy, refractory epilepsy and immunoglobulin treatment – unusual case report and review of the literature. Acta Paediatr. 2010; 99: 1903–1905.
- 55Vernino S, Geschwind M, Boeve B. Autoimmune encephalopathies. Neurologist. 2007; 13: 140–147.
- 56Chang JS, Chang TC. Hashimoto's encephalopathy: report of three cases. J Formos Med Assoc. 2014; 113: 862–866.
- 57Marshall GA, Doyle JJ. Long-term treatment of Hashimoto's encephalopathy. J Neuropsychiatry Clin Neurosci. 2006; 18: 14–20.
- 58Mijajlovic M, Mirkovic M, Dackovic J, Zidverc-Trajkovic J, Sternic N. Clinical manifestations, diagnostic criteria and therapy of Hashimoto's encephalopathy: report of two cases. J Neurol Sci. 2010; 288: 194–196.
- 59Hussain NS, Rumbaugh J, Kerr D, Nath A, Hillis AE. Effects of prednisone and plasma exchange on cognitive impairment in Hashimoto encephalopathy. Neurology. 2005; 64: 165–166.
- 60Pranzatelli MR, Tate ED, Travelstead AL, Longee D. Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome. Pediatrics. 2005; 115: e115–e119.
- 61Jacob S, Rajabally YA. Hashimoto's encephalopathy: steroid resistance and response to intravenous immunoglobulins. J Neurol Neurosurg Psychiatry. 2005; 76: 455–456.
- 62Kim JE, Choi HC, Song HK, et al. Levetiracetam inhibits interleukin-1 beta inflammatory responses in the hippocampus and piriform cortex of epileptic rats. Neurosci Lett. 2010; 471: 94–99.
- 63Stienen MN, Haghikia A, Dambach H, et al. Anti-inflammatory effects of the anticonvulsant drug levetiracetam on electrophysiological properties of astroglia are mediated via TGFβ1 regulation. Br J Pharmacol. 2011; 162: 491–507.
- 64Wong LC, Freeburg JD, Montouris GD, Hohler AD. Two patients with Hashimoto's encephalopathy and uncontrolled diabetes successfully treated with levetiracetam. J Neurol Sci. 2015; 348: 251–252.
- 65Litmeier S, Prüss H, Witsch E, Witsch J. Initial serum thyroid peroxidase antibodies and long-term outcomes in SREAT. Acta Neurol Scand. 2016. DOI: 10.1111/ane.12556. [Epub ahead of print].
- 66Ferracci F, Bertiato G, Moretto G. Hashimoto's encephalopathy: epidemiologic data and pathogenetic considerations. J Neurol Sci. 2004; 217: 165–168.